Y-Intercept (HK)’s Arcutis Biotherapeutics ARQT Stock Holding History

Y-Intercept (HK)’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.98M	Buy	+75,572	New	+$1.76M	0.04%	709
2025 Q4	–	Sell	-37,869	Closed	-$714K	–	1523
2025 Q3	$714K	Buy	+37,869	New	+$597K	0.02%	1124
2024 Q3	–	Sell	-37,730	Closed	-$351K	–	1291
2024 Q2	$351K	Buy	+37,730	New	+$341K	0.02%	972
2024 Q1	–	Sell	-15,804	Closed	-$51K	–	1351
2023 Q4	$51K	Buy	+15,804	New	+$43K	﹤0.01%	1160

Other funds holding ARQT

Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

AAM

AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $188M AUM

MWS

MFA Wealth Services Thousand Oaks, California $167M AUM 20.54% 1-Year Est. Return

YMRC

Yorktown Management & Research Company Forest, Virginia $163M AUM 68.53% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Y-Intercept (HK)'s ARQT Position: Q2 2026 in Review

Y-Intercept (HK) opened a new position in Arcutis Biotherapeutics (ARQT) in Q2 2026: 75,572 shares worth $1.98M. The stake represents 0.04% of the portfolio and ranks #709 among its holdings. This is a return to the name: Y-Intercept (HK) previously reported a position in ARQT as recently as Q3 2025.

Y-Intercept (HK) first reported a position in ARQT in Q4 2023 and has held it in 4 quarters since. 29 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

Y-Intercept (HK) held 75,572 shares of Arcutis Biotherapeutics worth $1.98M as of Q2 2026.
Arcutis Biotherapeutics was a new Y-Intercept (HK) position in Q2 2026.
Arcutis Biotherapeutics made up 0.04% of Y-Intercept (HK)'s portfolio in Q2 2026, its #709 holding.
Y-Intercept (HK) first reported a position in Arcutis Biotherapeutics in Q4 2023 and has held it in 4 quarters since.
29 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.